About EndoSphere Inc.
Founded in 2006, EndoSphere Inc. is a pioneer of endoscopically-insertable medical technologies. The company has developed a portfolio of intellectual property assets including 25 issued and pending U.S. and international patents. Its flagship product, the Satisphere™ System, is a noninvasive treatment for one of the world’s largest health issues: obesity and its co-morbidities. The SatiSphere device improves the regulation of appetite and satiety by using the body’s natural physiology. Use of the device does not require any incision and is reversible and repeatable. Clinical studies have shown that the device enables obese patients to achieve significant weight loss without invasive surgery or medication.
Worldwide obesity rates have become staggering. According to the Centers for Disease Control (CDC), obesity rates increased so dramatically during the past decade that today, more than 35 percent of U.S. adults suffer from obesity. By comparison, in 2000, not a single U.S. state had an obesity rate above 30 percent. Annual costs attributed to obesity and its co-morbidities are currently estimated at $147 billion and rising.
EndoSphere is a portfolio company of Broadline Capital, a global private equity investment firm. Major co-investors include Ohio TechAngel Funds II and III, Co-Investment Fund, Glengary, EI Millstream Investment, North Coast Angel Fund II, Physician Investment Group, and QCA First Fund III.
EndoSphere CEO, James McKinley explains the technology
